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ORIGINAL ARTICLE
See Editorial by Krainski and Birgersdotter-Green
BACKGROUND: In clinical trials, manufacturer-specific, strategic 
programming of implantable cardioverter–defibrillators (ICDs), including 
faster detection rates, reduces unnecessary therapy but permits 
therapy for ventricular tachycardia/ventricular fibrillation (VF). Present 
consensus recommends a generic rate threshold between 185 and 
200 beats per minute, which exceeds the rate tested in clinical trials 
for some manufacturers. In a case series, we sought to determine the 
relationship between programmed parameters and failure of modern 
ICDs to treat VF.
METHODS AND RESULTS: We reviewed cases in which normally 
functioning ICDs failed to deliver timely therapy for VF from April 2015 
to January 2017 at 4 institutions. Of 10 ambulatory patients, 5 died from 
untreated VF, 4 had cardiac arrests requiring external shocks, and 1 was 
rescued by a delayed ICD shock. VF did not satisfy programmed detection 
criteria in 9 patients (90%). Seven of these patients had slowest detection 
rates that were consistent with generic recommendations but not tested 
in a peer-reviewed trial for their manufacturer’s ICDs. Manufacturer-
specific factors interacted with fast detection rates to withhold therapy, 
including strict VF episode termination rules, enhancements to minimize 
T-wave oversensing, and features that restrict therapy to regular rhythms 
in ventricular tachycardia zones. Untreated VF despite recommended 
programming accounted for 56% of sudden deaths and 11% of all 
deaths during the study period.
CONCLUSIONS: Complex and unanticipated interactions between 
manufacturer-specific features and generic programming can prevent 
therapy for VF. More data are needed to assess the risks and benefits of 
translating evidence-based detection parameters from one manufacturer 
to another.
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Reliable sensing and detection of ventricular fi-brillation (VF) and rapid, life-threatening ven-tricular tachycardia (VT) was a challenge for 
early implantable cardioverter–defibrillators (ICDs). 
Manufacturers responded with improved technology; 
in this century, reports of failure to treat life-threaten-
ing VT or VF have been rare and limited to one1–4 or 
a few patients.5,6
In the last decade, investigators focused on prevent-
ing unnecessary ICD therapies by strategic program-
ming, including faster detection rates, longer detection 
times, discriminators for supraventricular tachycardia 
(SVT), and enhancements to prevent oversensing.7 
Clinical studies8–13 report that strategic programming 
reduces unnecessary therapies without withhold-
ing therapy for life-threatening VT/VF. Each study 
used ICDs from a single manufacturer. Programmed 
parameters were strictly controlled within each study, 
but they varied among studies. The 2015 HRS/EHRA/
APHRS/SOLAECE Consensus Statement on Optimal 
ICD Programming and Testing7 (Consensus Statement) 
provides generic programming recommendations. For 
some ICDs, these recommendations are necessarily 
extrapolated from evidence obtained using another 
manufacturer’s ICDs with different sensing and detec-
tion features. In a series of cases, we sought to deter-
mine the reasons that contemporary ICD systems failed 
to deliver therapy for life-threatening VT/VF in the era 
of strategic programming.
METHODS
Patient Selection
The 10 patients were ambulatory, expected to live >1 year, 
and did not have an acute illness. They met these criteria: 
(1) a shock for life-threatening VT/VF was either not deliv-
ered or delayed significantly, resulting in death or a major 
adverse event. For simplicity, we refer to failure to deliver 
timely therapy. (2) The ICD system functioned normally. 
(3) VT/VF detection and therapies were programmed ON. 
(4) The amplitude of sinus-rhythm R waves exceeded 5 
mV at implant and follow-up. Index events occurred 
from April 2015 to January 2017. No patient who met 
the inclusion criteria was excluded. Patients 1 to 8 were 
programmed and followed at 1 of the 4 participating 
WHAT IS KNOWN
• In clinical trials, manufacturer-specific, strate-
gic programming of implantable cardioverter–
defibrillators (ICDs) reduces unnecessary therapy 
but permits therapy for ventricular tachycardia/
fibrillation.
• Present guidelines provide generic programming 
recommendations. For some ICDs, these rec-
ommendations are extrapolated from evidence 
obtained using other manufacturer’s ICDs with dif-
ferent sensing and detection features.
WHAT THE STUDY ADDS
• No patient with manufacturer-specific, program-
ming validated in a clinical trial failed to receive an 
initial, timely shock for ventricular fibrillation.
• Most patients who did not receive timely ven-
tricular fibrillation shocks had ICDs programmed 
consistent with guidelines extrapolated from 
evidence obtained using another manufactur-
er’s ICDs with different sensing and detection 
features.
• More data are needed to assess both the ben-
efits and risks of applying generic programming 
recommendations to specific ICDs in which 
these recommendations have not been validated 
clinically.
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institutions; patients 9 and 10 were programmed and 
followed at a community hospital; they were brought to 
a participating institution for tertiary care during their 
index events. To estimate completeness of inclusion, 
we reviewed all deaths and resuscitated cardiac arrests 
in ICD patients during the study period at the 2 institu-
tions that tracked these data. This study was approved by 
the Institutional Committees on Human Research at the 
authors’ institutions.
ICD Programming: Compliance With 
Recommendations
The Consensus Statement7 provides 32 generic recom-
mendations for tachycardia detection. Its online Appendix 
B provides programming examples that may be considered 
manufacturer-preferred values.
We reviewed programming for compliance or noncompli-
ance with both generic and manufacturer-preferred recom-
mendations that influence detection of VT/VF, including rate 
threshold and SVT discriminators. Programmed sensitivity and 
duration also influence detection; but, in all study patients, 
sensitivity was nominal and noncompliant durations were 
shorter than recommended, increasing rather than decreas-
ing the likelihood of VT/VF detection.
The Consensus Statement recommends programming 
the slowest rate threshold between 185 and 200 beats per 
minute for primary prevention and ≤200 beats per minute 
for secondary prevention (but at least 10 beats per min-
ute below the clinical VT rate),7 independent of whether 
this rate defines a VT or VF zone. For each manufacturer, 
Appendix B provides both a single, preferred rate threshold 
and a range of acceptable rate thresholds that are within 
guidelines. For primary prevention patients, preferred 
rate thresholds vary from 185 to 188 beats per minute; 
the range of acceptable thresholds extends from the pre-
ferred value to 200 beats per minute. For some ICDs, the 
Consensus Statement and its Appendix B permits more 
restrictive programming than tested in clinical trials,8–13 
restricting therapy to faster rates.
RESULTS
Table  1 summarizes patient demographics. Table I in 
the Data Supplement shows device and implant data. 
Table 2 shows programmed parameters. One column 
indicates whether rate threshold programming com-
plied with the generic recommendations of the Con-
sensus Statement (consensus recommendations) and 
by extension was within guidelines as determined by 
Appendix B. A second column indicates whether the 
rate threshold equaled Appendix B’s preferred thresh-
old for the specific manufacturer. Table 3 summarizes 
manufacturer-specific features that contributed to fail-
ure to deliver timely shocks.
Of the 8 patients who underwent implant testing, 
all had reliable sensing and detection of VF (maxi-
mum delay 1 s). Overall, 5 patients died of untreated 
VF, 4 patients required external defibrillation, and 1 
patient was rescued by the ICD after aborted shocks. 
There was no evidence of a primary cause of car-
diac arrest (eg, acute myocardial infarction, pulmo-
nary embolus) in the 5 survivors or 3 patients who 
died after prolonged resuscitation. The flow chart in 
Figure 1 summarizes reasons for failure to deliver VF 
therapy.
Programming Consistent With Generic 
Consensus Recommendations (Cases 1 to 8)
In cases 1 to 8, rate thresholds complied with generic 
consensus recommendations; and SVT-VT discrimina-
tors complied with manufacturer preferences in Appen-
dix B.7
Premature VF Episode Termination (Cases 1  
and 2)
In 2 cases, ICDs detected VF, but the device-defined VF 
episode terminated prematurely because of intermit-
tent undersensing.
Case 1
A 66-year-old man with a primary prevention St. Jude 
Medical ICD had VF that was detected rapidly and 
defibrillated with a single shock. His physician found 
no change in clinical status and made no changes in 
programming or medication. Two months later, the 
patient had a witnessed, out-of-hospital cardiac arrest. 
Paramedics defibrillated him from VF 13 minutes after 
collapse. Spontaneous circulation returned, but he died 
of anoxic encephalopathy.
Analysis. Figure  2 shows that the stored electro-
gram (EGM) began with monomorphic VT slower 
than the programmed VT detection interval (315 ms, 
190 beats per minute); this VT degenerated to VF. The 
ICD detected VF, but terminated the device-defined 
VF episode prematurely (Return to Sinus), aborting 
the shock because it undersensed VF EGMs. After 
this, the ICD neither detected VF nor stored EGMs 
before paramedics performed external defibrillation. 
The shock would have been delivered if the VT inter-
val had been programmed to the clinically validated 
value of 333 ms (180 beats per minute)12 rather 
than the manufacturer-preferred value (Consensus 
Statement Appendix B7; Figure 2 and Figure I in the 
Data Supplement).
Case 2
A 76-year-old male with a secondary prevention St. 
Jude Medical ICD for out-of-hospital VF in 2008 pre-
sented with syncope in 2015.
Analysis. Figure 3 shows that premature episode ter-
mination occurred for the initiating VT because anti-
tachycardia pacing slowed the VT to 318 to 332 ms 
(180–189 beats per minute) below the rate threshold of 
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300 ms (200) beats per minute. This episode would not 
have terminated prematurely if the VT interval had been 
programmed to the clinically validated value of 333 ms 
(180 beats per minute).12 VT then degenerated to VF. 
Three VF episodes terminated prematurely because of 
undersensing. It is likely that sensing enhancements 
designed to prevent T-wave oversensing14 contributed 
to undersensing VF (Figure II in the Data Supplement).
Table 1. Clinical Data
Case Age, y Sex Heart Disease LVEF NYHA Class Indication β Blocker Antiarrhythmic
1 66 M CAD 0.30 2 1°→2° (VF) Y Amiodarone
2 76 M CAD 0.40 1 2° (VF) Y N
3 62 M CAD 0.25 2 1° Y N
4 79 M CAD 0.20 3 1°→2° (VT) Y N
5 41 M CAD 0.18 3 1° Y N
6 87 M CAD 0.35 2 1° Y N
7 75 M CAD 0.20 3 2° (VF) Y N
8 67 M NICM 0.45 2 2° (VF) Y N
9 14 M Vasospastic MI 0.35 2 1°→2° (VT) N Amiodarone
10 44 M NICM 0.20 3 1°→2° (VT) Y Amiodarone Mexiletine
1° indicates primary prevention for implantable cardioverter–defibrillator (ICD), 2° indicates secondary prevention for ICD, 1°→2° indicates 
primary prevention indication at implant with a subsequent VT or VF requiring ICD therapy. CAD indicates coronary artery disease; LVEF, 
left ventricular ejection fraction; M, male; MI, myocardial infarction; N, no; NICM, nonischemic cardiomyopathy; NYHA, New York Heart 
Association; VF, ventricular fibrillation; VT, ventricular tachycardia; and Y, yes.
Table 2. Programmed Parameters
Case
Sensitivity 
(mV) Sensing Enhancements
Monitor 
(beats per 
minute/ms)
VT/VT1 
(beats per 
minute/ms); 
Duration
FVT/VT2 
(beats per 
minute/ms); 
Duration
VF (beats per 
minute/ms); 
Duration
Programmed Rate Threshold  
Consistent with†
Clinical 
Evidence
Generic 
Range
Manufacturer-
Preferred Value
1 0.5*
LFA, Decay Delay 60 ms, 
Threshold Start 50%, 
SecureSense
OFF OFF
190/315*; 24 
intervals
250/240*; 12 
intervals
No (VT2 and 
VF)12
Yes
VT2: No
VF: Yes
2 0.3
Decay Delay 60 ms, 
Threshold Start 62.5%
OFF OFF
200/300*; 30 
intervals
240/250*; 12 
intervals
No (VT2 and 
VF)12
Yes
VT2: No
VF: Yes
3 0.3 None
150/400; 32 
intervals
OFF OFF
200/300*; 
30/40 intervals
No (VF)8–10,13 Yes No
4 0.5*
LFA, Decay Delay 60 ms, 
Threshold Start 50%, 
SecureSense
OFF OFF
200/300*; 18 
intervals
250/240*; 12 
intervals
No (VT2 and 
VF)12
Yes
VT2: No
VF: Yes
5 0.3
T-wave rejection, RV lead 
noise, LIA
Monitor 
150/400; 44 
intervals
OFF
188/320*; 40 
intervals
200/300*; 
18/24 intervals
No (VF) 8–10,13 Yes No (FVT, VF)
6 0.3
T-wave rejection, RV lead 
noise, LIA
OFF
150/400; 32 
intervals
200/300*; 
30/40 intervals
230/261*; 
30/40 intervals
No (VF)8–10,13 Yes No
7 0.8 None OFF
150/400*; 26 
intervals
182/330*; 22 
intervals
231/260*; 
18/24 intervals
No data Yes Yes
8 0.6 None 160/375; 30 s OFF 200/300*; 5 s 250/240; 2.5 s Yes11 Yes No
9 0.5*
LFA, Decay Delay 60 ms; 
Threshold Start 50%; 
SecureSense
169/355; 18 
intervals
OFF
200/300*; 30 
intervals
250/240*; 18 
intervals
No12 No
VT2: No
VF: Yes
10 0.3
T-wave rejection, RV lead 
noise, LIA
167/360; 32 
intervals
OFF
200/300*; 
30/40 intervals
240/250*; 
30/40 intervals
No (FVT, 
VF)8–10,13
No No (FVT, VF)
FVT indicates fast VT zone; LFA, low-frequency attenuation filter; LIA, Lead Integrity Alert; RV, right ventricular; VF, ventricular fibrillation; and VT, ventricular tachycardia.
*Values indicate sensing thresholds and detection rate thresholds not tested in clinical trials.
†Clinical Evidence denotes values programmed in referenced peer-reviewed clinical trials. Generic Range denotes recommended range in Consensus Statement. 
Manufacturer-preferred value denotes value indicated in the Consensus Statement.
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VF Never Detected (Cases 3 to 7)
In 4 cases, the ICD did not detect the index episode of VF.
Case 3
A 62-year-old man with a primary prevention Medtron-
ic cardiac resynchronization therapy ICD died sudden-
ly and unexpectedly in his bedroom. A Lead Integrity 
Alert15 was triggered by double-counted EGMs and 
transmitted to a remote monitoring network.
Analysis. Figure 4 and Figure III in the Data Supplement 
show transmitted EGMs. In each Figure, Panel 1 shows 
the onset of monomorphic VT as a device-defined non-
sustained episode, triggered by intervals that are tran-
siently shorter than the VF detection interval of 300 ms. 
EGMs from multiple nonsustained episodes over the 
next 46 minutes show that VT slowed to cycle length 
290 to 330 ms and degenerated to polymorphic VT/
VF. Monomorphic VT would have been detected with a 
clinically validated VF interval of 330 ms (182 beats per 
minute)8,9; transmitted data are insufficient to deter-
mine whether detection would have occurred with the 
validated value of 320 ms (188 beats per minute).10,13
Case 4
A 79-year-old man with a primary prevention St. 
Jude Medical cardiac resynchronization therapy ICD 
had monomorphic VT with cycle length 260 to 280 
ms in December 2016 that was detected and treated 
in the VT zone (240–300 ms). In January 2017, he 
had a witnessed cardiac arrest while sitting in a chair. 
Cardiopulmonary resuscitation was performed until 
paramedics arrived 9 minutes later and defibrillated 
him from polymorphic VT/VF to sinus rhythm (Figure 
IVA in the Data Supplement). He died despite pro-
Table 3. Causes of Failure of Timely VF Therapy
Case
Recommended 
Programming
ICD Response to Clinical Arrhythmia
Root Cause of Failure to 
Treat Clinical VT/VF Additional FactorsVT (Cycle Length) VF
1 Yes No therapy (395–345 ms) No therapy
VT: Rate
Features to prevent 
T-wave oversensing*VF: Premature episode 
termination; rate and duration
2 Yes 270–320 ms Therapy delay >1 min Premature episode termination
Features to prevent 
T-wave oversensing*
3 Yes No therapy (300–320 ms) No therapy VT/VF: Rate and duration  
4 Yes … No therapy Rate and duration
Features to prevent 
T-wave oversensing
5 Yes No therapy (310–350 ms) No therapy
VT: Rate, Consecutive interval 
counting  
VF: Rate and duration
6 Yes … No therapy VF: Rate and duration
Consecutive interval 
counting (VT zone)
7 Yes No therapy (344–375 ms) Therapy delay 14 min
VT: Onset Onset and stability 
discriminatorsVF: Rate and stability
8 Yes No therapy (375–345 ms)
No therapy after  
6th shock
VT: Rate
 VF: Postshock undersensing, 
rate and duration
9 No No therapy (345–360 ms) No therapy
VT: Rate Features to prevent 
T-wave oversensing*VF: Rate and duration
10 No No therapy (300–330 ms) Therapy delay 9 min
VT: Rate
 
VF: Rate and duration
ICD indicates implantable cardioverter–defibrillator; VF, ventricular fibrillation; and VT, ventricular tachycardia.
*Decay Delay, Threshold Start, low-frequency attenuation (LFA) filter.
Figure 1. Flow chart summarizes implantable  
cardioverter–defibrillator (ICD) programming and 
reasons for failure to deliver timely ventricular fibrilla-
tion (VF) therapy.
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Figure 2. Case 1. Stored electrogram (EGM) displays 3 of 4 continuous panels showing filtered atrial EGM (A Sense 
Amp), filtered right ventricular (RV) sensing EGM (V Sense Amp), shock EGM (RV coil Can, discrimination), dual-
chamber markers, ventricular intervals in ms, and timeline in s (Figure I in the Data Supplement).  
Panel 1 shows ongoing monomorphic ventricular tachycardia (VT) at cycle length of 387 to 395 ms, slower than (Continued )
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longed resuscitation. During resuscitation, he had 3 
episodes of monomorphic VT that the ICD detected 
and treated.
Analysis. Figure IVB in the Data Supplement shows the 
first of 3 similar episodes. Each persisted for an unknown 
duration with cycle length slower than the VT interval 
(300 ms) before accelerating into the VT zone. The sub-
sequent stored VTs suggest that untreated VF may have 
begun with VT slower than the detection interval and 
that this VT degenerated to VF, which was undersensed.
Case 5
A 41-year-old man suffered an arrhythmic cardiac arrest 
on in-hospital telemetry, the night after elective implan-
tation of a primary prevention Medtronic ICD. He had 
no metabolic abnormalities, and he received no anti-
arrhythmic drugs. After resuscitation, he required ino-
tropic support and underwent heart transplantation 6 
weeks later.
Analysis. Figure 5A shows that initial episode of low-
frequency VF did not fulfill the programmed detection 
criteria for either VF (18/24 intervals shorter than 300 
ms) or VT (40 consecutive intervals,16 300–319 ms). 
Double counting triggered the Lead Integrity Alert,15 
which extended the number of intervals to detect VF to 
30 of 40. After external defibrillation, monomorphic VT 
occurred and degenerated to polymorphic VT with cycle 
length 310 to 350 ms (Figure VB in the Data Supplement). 
This required a second external defibrillation (Figure 5C 
Panel 2). High-frequency VF recurred a 2 s later (Figure 5C 
Panel 3; Figure V in the Data Supplement).
Case 6
An 87-year-old man with complete heart block and a 
primary prevention Medtronic cardiac resynchroniza-
tion therapy ICD had a cardiac arrest while sleeping. His 
caregiver called 911. Paramedics found him in VF and 
defibrillated him to pulseless electric activity, but he did 
not regain spontaneous circulation. The ICD transmit-
ted a Lead Integrity Alert.
Analysis. The transmitted EGMs in Figure VI in the 
Data Supplement show VF with undersensing that 
never fulfilled the detection criteria for VF (30/40 
intervals shorter than 300 ms). Further, detection of 
VT did not occur despite a slow VT interval (400 ms) 
because Medtronic uses consecutive interval counting 
in the VT zone. Undersensing or entrance block caused 
occasional device-measured intervals slower than the 
VT interval, which repeatedly reset the VT count to 0 
(Figure VI in the Data Supplement).
Case 7
A 75-year-old man with long-standing atrial fibrillation 
had an ICD implanted in 1994 for out-of-hospital VF 
and upgraded in 2011 to a Biotronik cardiac resynchro-
nization therapy ICD. In 2015, his electrophysiologist 
increased the VT detection interval to 400 ms after the 
patient had suspected arrhythmic syncope. One month 
later, he had a witnessed cardiac arrest followed by 
immediate cardiopulmonary resuscitation. Paramed-
ics found him in VF and defibrillated him to pulseless 
electric activity. He died after a prolonged resuscitation 
including repetitive sequences of VF.
Analysis. Relevant ICD parameters include detection 
intervals consistent with recommended secondary pre-
vention programming (VT1: 400 ms, VT2: 330 ms, VF: 
260 ms) and nominal values of single-chamber SVT-VT 
discriminators: Onset at 20% and Stability at 24 ms.7,17 
Stored EGMs at the time of collapse recorded mono-
morphic VT at cycle length 375 to 344 ms in the VT 
Figure 2 Continued. the programmed VT detection interval of 315 ms. The rhythm becomes polymorphic at 6 s (end of Panel 
1) and then degenerates to VF, which is detected at 13.4 s (beginning of Panel 3). The ICD delivers antitachycardia pacing (ATP, 
STIM markers, 13.4–14.9 s) while charging (line of small asterisks, 13.4–21.8 s). However, at 22.4 s (Panel 4), the ICD classifies 
the rhythm as sinus, aborting the shock and resetting VT and ventricular fibrillation (VF) counters to 0 (Return to Sinus marker). 
Markers denote intervals classified (binned) in the Sinus zone (VS), VT zone (T), or VF zone (F). Intervals are not binned (−) in any 
zone if zones differ for the index interval and its average with preceding 3 intervals.14 Return to Sinus occurs when a programmable 
number of consecutive classified (binned) intervals are slower than the slowest detection interval. In this case, Return to Sinus was 
programmed to the nominal value of 5 intervals (range 3–7 intervals). Subsequently, clinical polymorphic VT/VF did not satisfy 
the programmed number of intervals to detection VT (24 intervals shorter than 315 ms) or VF (12 intervals shorter than 240 ms). 
Undersensing of low-amplitude VF EGMs after high-amplitude VF EGMs was critical in erroneous premature termination of the 
device-defined VF episode and aborting the shock. Arrows in Panel 3 denote that 6 sequential VF EGMs are not sensed after a high 
amplitude because EGM amplitude decreases faster than dynamically adjusting sensitivity can adapt. Features to prevent T-wave 
oversensing may also have contributed to undersensed EGMs. Signals with comparably low amplitude were sensed reliably toward 
the end of Panel 2 (Figure I in the Data Supplement). The final undersensing event occurs at 21.2 s (Panel 4) after 3 sequentially un-
dersensed EGMs with amplitude 0.91 to 1.1. mV (third upward arrow). Undersensing these EGMs results in a device-defined ven-
tricular interval of 852 ms (VS marker). The subsequent EGM is sensed accurately with an interval of 332 ms (black box), resulting 
in the fifth consecutive binned, VS interval (†) and premature episode termination. However, if VT detection had been programmed 
to clinically tested value of 333 ms, the 332 ms interval would have been unclassified (−), and premature episode termination 
would not have occurred. Because the ICD completed charging during the 852 ms interval (end of line of asterisks), it would have 
delivered the shock synchronous with the EGM ending the 254 ms interval after the † EGM (first binned VT or VF interval after 
charging). STIM indicates ventricular antitachycardia pacing; VS, ventricular sensed event; and VVI, ventricular demand pacing.
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Figure 3. Case 2. Stored electrograms (EGMs) display filtered right ventricular (RV) dedicated bipolar sensing EGM 
(V Sense Amp), ventricular markers, ventricular intervals in ms, and timeline in s.  
These multiple device-defined episodes were recorded during a single clinical ventricular tachycardia/ventricular fibrillation (VT/
VF) episode. A, Monomorphic VT. Discontinuous Panels 1 and 3 show that VT begins an unknown time before the recording. 
The VT cycle length straddles the Sinus VT boundary of 300 ms so that multiple intervals in Panel 2 remain unclassified. VT is 
detected at 15.4 s in Panel 3 (VT(ATP—-…)) and antitachycardia pacing (ATP) is delivered immediately (STIM markers). After 
ATP, VT slows to 318 to 332 ms in the Sinus zone, resulting in episode termination (Return to Sinus; B) VF. The next stored 
EGM recorded about a minute later showed detection of VF. It is likely that the monomorphic VT degenerated (Continued )
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zone that did not fulfill the Onset criterion and was 
thus classified as SVT (Figure 6A). The stored EGM in 
Figure 6B was recorded 13 minutes later and shows VF. 
Because of intermittent undersensing, the calculated 
ventricular cycle length (276 ms) was in the VT2 zone, 
so the Stability algorithm was applied and determined 
that the rhythm was irregular. Thus, the ICD classified 
VF as SVT and withheld therapy (Figure 6).
Postshock Undersensing (Case 8)
Case 8
A 67-year-old man underwent Boston Scientific ICD 
implantation with an integrated bipolar lead after 
out-of-hospital VF. One month later, he suffered a wit-
nessed cardiac arrest. Paramedics arrived 12 minutes 
later and defibrillated VF after a long resuscitation. 
With prolonged hospitalization, the patient recovered 
completely and underwent VT ablation.
Analysis. Figure VII in the Data Supplement shows 
monomorphic VT that degenerated to VF, which was 
detected and defibrillated to sinus rhythm. This initi-
ated a repetitive sequence of recurrent VF followed 
by successful defibrillation. However, the amplitude 
of the sensed EGMs decreased progressively in suc-
cessive postshock recurrences of VF until they were 
undersensed consistently and VF remained undetected 
(Figure VII in the Data Supplement).
Deviation From Consensus Programming 
(Cases 9 to 10)
In case 9, the VT interval was set to 300 ms after appar-
ently successful ablation of slower VT; the patient pre-
sented with VT slower than 300 ms and subsequent 
undersensed VF (Figure VIII in the Data Supplement). 
In case 10, the VT detection interval was not increased 
after antiarrhythmic drug treatment was changed (Fig-
ure IX in the Data Supplement; Data Supplement).
Completeness of the Data Set
No patient who met the study criteria was knowingly 
excluded. We reviewed all cardiac arrests and other 
deaths in ICD patients during the study period at the 2 
institutions that tracked these data. These institutions 
contributed 8 of 10 cases, including 3 of the 4 cardiac 
arrest cases and all 5 fatal cases. There were no other 
resuscitated cardiac arrests during the study period. 
Of 47 total decedents during the study period, 9 died 
suddenly. In addition to the 5 study patients who died, 
2 patients died of pulseless electric activity, 1 patient 
with a fractured defibrillation lead died of VF that was 
detected but not defibrillated, and 1 patient died sud-
denly without postmortem ICD interrogation (Table II in 
the Data Supplement). Thus, failure to detect VF despite 
recommended programming was responsible for 5 of 8 
adjudicated sudden deaths (62%), 56% of total sud-
den deaths, and 11% of all deaths in ICD patients.
DISCUSSION
We present a series of contemporary ICD patients who 
did not receive timely VF shocks. Our principal finding is 
that, in most patients, ICD programming deviated from 
values validated in manufacturer-specific, clinical tri-
als,8–13 which form the evidence base for the Consensus 
Statement,7 but they complied with more restrictive, 
generic recommendations of the Consensus Statement. 
Failure to detect VF despite generically recommended 
programming was the most common cause of sudden 
death at the 2 centers that tracked these data. These 
data suggest that differences in sensing and detection 
methods among manufacturers may limit the applica-
bility of generic programming recommendations.
Prior Studies: Programming Sensing and 
Detection of VT/VF
In the last decade, randomized clinical trials9–12 and pro-
spective observational studies8,13 in primary prevention 
patients found that faster rate thresholds of 180 to 200 
beats per minute and longer durations of at least 6 to 12 
s reduce unnecessary shocks8–13 and may reduce mor-
tality.18 Programmed parameters were tightly controlled 
within each study using ICDs from a single manufacturer, 
but varied among studies using different manufacturers’ 
ICDs. Importantly, studies report no deaths from untreat-
ed VT/VF. Programmed, slowest rate thresholds were 
182 to 188 beats per minute for Medtronic ICDs8–10,13 (VF 
zone), 180 beats per minute for St. Jude ICDs12 (VT zone), 
and 200 beats per minute for Boston Scientific ICDs11 
(VF zone). Data on strategic programming of secondary 
prevention patients are limited to subgroup analyses of 
1 randomized19 and 1 observational study,13 each using 
Medtronic ICDs; these data support programming 188 
beats per minute if the clinical VT is faster than this rate.
Figure 3 Continued. to VF in the interval between the 2 recordings. Figure IIB in the Data Supplement shows sequential VF 
episodes 1 to 3 in which VF detection criteria were met, but shocks were aborted because of undersensing that caused premature 
episode termination. Figure 3B displays only episode 3 (Panel 5). The mV calibration marker shows that VF EGMs have relatively high 
base peak amplitudes of 5 to 10 mV for larger EGMs and 1 to 2 mV for most undersensed EGMs. Asterisks denote selected under-
sensed EGMs that contributed to premature episode termination because of combined effects of highly variable EGM amplitudes, 
fast programmed detection interval, the high programmed Threshold Start of 62.5%, and the programmed Decay Delay of 60 ms 
(Figure X in the Data Supplement). STIM indicates ventricular antitachycardia pacing; SVT, supraventricular tachycardia; and VS, 
ventricular sensed event.
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Figure 4. Case 3. Electrograms (EGMs) and interval plot transmitted with Lead Integrity Alert.  
Atrial, right ventricular (RV) wide-band filtered sensing channel (RV Tip-RV Ring), and dual-chamber marker channel are shown.  
Panel 1, Onset of monomorphic ventricular tachycardia (VT) at 10:02. Event storage is triggered by the 8 intervals (Continued )
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The Consensus Statement7 relied on this evidence 
to develop generic programming recommendations 
including a range of reasonable heart rate cutoffs that 
are inclusive of those proven in good-quality trials. Its 
online Appendix B provides manufacturer-preferred 
examples intended to best approximate the recom-
mended behaviors for each available ICD model.
Present Study
In contrast to clinical trials8–13 in which no patient died from 
untreated VT/VF with manufacturer-specific program-
ming, we report patients with adverse outcomes. Overall, 
failure of VF to satisfy programmed detection criteria was 
critical in 9 of our 10 patients (90%, all but patient 8). 
Patients 1 to 8 had programming consistent with generic, 
Consensus Statement recommendations. However, in 
patients 1 to 6, programming was inconsistent both with 
manufacturer-specific, clinical trials and manufacturer-pre-
ferred values (online Appendix B). In patient 7, program-
ming complied with manufacturer-preferred values, but 
these values had not been validated in a peer-reviewed, 
clinical study. Programming a detection rate validated 
clinically for the manufacturer’s ICD would have resulted 
in prompt shocks for at least 4 other patients (1–3, 10); of 
these, patient 1 would not have received prompt shocks 
with manufacturer-preferred programming.
Our cases illustrate how variability of VF within patients 
necessitates a safety margin for detection: all 8 ICDs 
tested at implant detected VF reliably with the settings 
that failed to detect the index VF; 2 detected spontane-
ous VF or rapid VT before the index VF (cases 1, 4), and 
1 detected VF after external defibrillation (case 5). Over-
all, failure of VF therapy accounted for 11% of deaths in 
ICD patients at institutions that tracked these data. In a 
postmortem series, Tseng et al20 reported that similar 
failures accounted for 6% of deaths in ICD patients.
Interaction of Manufacturer-Specific Features 
With Generic Programming
Counting Methods, Detection Duration, and SVT 
Discriminators
Manufacturers use different methods to count ventricu-
lar intervals that satisfy rate criteria.14,16,17,21 Each method 
tolerates slow intervals in the VF zone. However, Bos-
ton Scientific tolerates more slow intervals (40%) than 
Medtronic (25%) or Biotronik (33%); yet only Boston 
Scientific ICDs have been tested with a slowest detection 
rate of 200 beats per minute and only for durations less 
than about 5 s.11 Patient 3 was programmed to 200 beats 
per minute using Medtronic counting for a longer dura-
tion (30/40 intervals) that was tested for slower rates of 
18210,13 or 188 beats per minute.8,9 Therapy would have 
been delivered with a threshold of 182 beats per min-
ute. Without a monitoring zone, we cannot determine 
whether therapy would have occurred with a threshold 
of 188 beats per minute. Similarly, we cannot determine 
whether validated programming would have resulted in 
prompt therapy in patients 4 and 5.
In addition, counting methods for the VT zone vary 
among manufacturers. Medtronic ICDs count consecu-
tive intervals.16 During VF in patient 6, the VT count was 
repeatedly reset to 0 by intermittent, device-measured 
intervals slower than the VT interval, which occurred 
because of undersensing or entrance block. Biotronik 
ICDs use up/down counting.17 In patient 7, VF with 
undersensing had a measured rate of 217 beats per 
minute (276 ms) in the VT2 zone. This constituted a 
problem because unvalidated, manufacturer-preferred 
programming of the Stability discriminator ≤231 beats 
per minute (260 ms) prevented detection of VF; Stability 
discriminators are of little value >200 beats per minute.
Episode Termination Rules
ICD-defined VT/VF episodes continue until the rhythm is 
classified as normal (sinus) based on (slow) rate and dura-
tion. Therapy is not delivered if the episode terminates 
prematurely. St. Jude Medical ICDs have the most sensi-
tive episode termination rule.14 Cases 1 and 2 show how 
it interacts with fast detection rates and occasional under-
sensing to withhold therapy after VF has been detected.
Enhancements to Minimize T-Wave Oversensing
St. Jude Medical sensing enhancements Decay Delay 
and Threshold Start14 (Figure X in the Data Supplement) 
increase ventricular blanking and have been associated 
with VF undersensing.1,20 The low-frequency attenua-
tion filter may reduce the amplitude of VF EGMs more 
than the amplitude of sinus-rhythm EGMs because VF 
EGMs have lower frequency content than sinus-rhythm 
EGMs.22 In the St. Jude Medical PROVIDE trial of stra-
tegic programming (Programming Implantable Cardio-
verter Defibrillators in Patients With Primary Prevention 
Indication to Prolong Time to First Shock),12 the detec-
tion rate was 180 beats per minute; use of Decay Delay 
Figure 4 Continued. shorter than the programmed ventricular fibrillation (VF) detection interval (300 ms FS markers). In Panel 
2 (continuous with Panel 1), VT cycle length then slows to 290 to 330 ms in the Monitor zone. The end of the dotted horizon-
tal line spanning Panels 1 and 2 indicates when VF would have been detected with a clinically validated detection interval of 
330 ms (182 beats per minute). The corresponding Monitor zone interval lasted 35 min. Rapid nonsustained VT episodes were 
stored intermittently for 46 min until 10:48 am (Figure V in the Data Supplement Panels 3 to 5). Panel 6, Last device-defined 
nonsustained episode. Ventricular intervals are denoted VS in the Sinus or Monitor zone, FS in the VF zone, BV for biventricu-
lar paced. Atrial markers denote pacing (AP, atrial paced event), blanking-period sensing (AB, sensed event in atrial blanking 
period), and refractory-period sensing (AR, sensed event in atrial refractory period).
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and Threshold Start were not controlled; and most ICDs 
predated the low-frequency attenuation filter. Thus, the 
interaction of these features with a detection rate of 
200 beats per minute is untested.
Additional Factors
Patients 8 to 10 illustrate known mechanisms of withhold-
ing VF therapy. In patient 8, postshock undersensing of 
VF occurred after repetitive shocks through an integrated 
bipolar lead.23 Patient 9 was considered cured of VT after 
ablation, so his ICD was set to primary prevention param-
eters; in studies of VT ablation, detection rates have not 
been reprogrammed after VT was rendered noninducible. 
Case 10 emphasizes the importance of reprogramming 
the detection rate when antiarrhythmic drugs are added.7
Role of Preceding Monomorphic VT in Withholding  
VF Therapy
Untreated monomorphic VT initiated polymorphic VT/VF 
in 7 of the 8 patients in whom we could determine the 
Figure 5. Case 5. Selected electrograms (EGMs) show right ventricular (RV) integrated bipolar EGM (RV Tip-RV Coil), 
shock EGM (Can-RV Coil), and ventricular markers.  
The implantable cardioverter–defibrillator (ICD) did not record the onset of ventricular fibrillation (VF). It recorded the first 
device-defined, nonsustained episode (episode 1) at 03:48. A, Nonsustained episode 6 at 03:49 is the last episode recorded 
before the first external defibrillation. VF EGMs have a low-frequency content and do not fulfill the programmed detection 
criteria for either VF (18/24 intervals shorter than 300 ms) or ventricular tachycardia (VT; 40 consecutive intervals shorter than 
320 ms). Intervals in the VT zone do not contribute to detection because consecutive interval counting causes each interval 
in the sinus zone (320 ms or greater) to reset the VT count to 0. Undetected recurrence of undetected monomorphic and 
polymorphic VT is shown in Figure VB in the Data Supplement. C, VF episode 9 at 03:55. Three continuous panels show poly-
morphic VT with cycle length 270 to 430 ms that does not satisfy interval/duration criteria for detection and requires a second 
external shock (Panel 2, up arrow). If the VF interval had been programmed to the clinically validated values of 320 or 330 ms, 
this polymorphic VT would have satisfied the programmed 18/24 intervals for detection of VF (end of dotted arrow in Panels 1 
and 2). However, the Lead Integrity Alert15 was activated incorrectly during Episode 5 when both oversensing criteria were ful-
filled. This alert increased the number of intervals for VF detection to 30/40 during Episode 6 and subsequent episodes. After 
the shock, VT recurred following the second paced beat and immediately accelerated to VF. The frequency content of EGMs 
was higher during this VF than during the first VF or the polymorphic VT above. The ICD detected VF rapidly and defibrillated 
it with a single shock (Figure VC to VC in the Data Supplement Panels 4 to 6).
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Figure 6. Case 7. Electrograms (EGMs) from 2 device-defined supraventricular tachycardia (SVT) episodes (device 
lifetime device episodes No. 39 and 40) recorded during cardiac arrest.  
Each panel shows markers, atrial EGM, right ventricular (RV) dedicated bipolar EGM, and left ventricular (LV) bipolar EGM. A, 
Monomorphic ventricular tachycardia (VT) with cycle length 367 to 383 ms in the VT 1 zone. The atrial EGM confirms atrio-
ventricular (A-V) dissociation with additional far-field R waves. This VT began during maximum rate sensor-driven pacing (not 
shown) and had a measured Onset of 19%, less than the 20% required to be classified as VT. B, Ventricular fibrillation (VF) 
with intermittent undersensed EGMs (asterisks). Most undersensed EGMs results from high-amplitude EGMs after low-ampli-
tude EGMs faster than dynamic sensitivity can adjust. Thus, the device measured a cycle length 276 ms, in the VT2 zone. The 
measured Stability of 148 ms exceeded both the nominal (programmed) value of 24 ms and the manufacturer recommended 
value of 40 ms required for classification as VT2.
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initiating rhythm. In at least 4 of these patients, clinically 
validated, manufacturer-specific programming would 
have treated VT before it degenerated to VF. Further, VF 
that arises from prolonged VT may be difficult to detect 
or treat. Although low-frequency VF has been consid-
ered an agonal rhythm, metabolic changes during VT 
may produce de novo, low-frequency VF (patients 3, 7, 
and 9) because of local conduction block or hyperkale-
mia, resulting in long device-detected intervals because 
of undersensing or entrance block.6 Patient 5’s first 
recorded rhythm was low-frequency VF, but recurrence 
of high-frequency VF promptly after the first defibrilla-
tion indicates that the presenting VF was not an agonal 
rhythm. In addition, prolonged VT may cause metabolic 
changes that facilitate early postshock recurrence of VT/
VF (eg, catecholamine release, patients 4, 5, 7–9).
Clinical Implications
VF detection algorithms must be robust against device-
detected intervals slower than the rate threshold to 
compensate for undersensing, entrance block, or 
detection restrictions applied in VT zones. Both fast 
detection rates and enhancements that facilitate under-
sensing increase the fraction of such device-detected, 
slow intervals. When devices measure slow intervals, 
strict counting methods and the Stability discriminator 
reduce sensitivity for detecting VF in VT zones; sensi-
tive episode termination rules reduce the likelihood that 
VF therapy will be delivered once VF is detected; and 
long detection times enhance both effects. Finally, fast 
detection rates may increase the likelihood that VT will 
not be detected until it degenerates to low-frequency 
VF, which may be difficult to detect.
Ideally, programming should deliver all life-saving 
ICD therapy but no unnecessary therapy. Practically, the 
programmer’s dilemma is to balance the risks of fail-
ure to treat VF with the risks of inappropriate therapies. 
Although evidence-based, manufacturer-specific pro-
gramming may withhold necessary therapy, the absence 
of deaths from untreated VF in the 6414 patients in 
strategic programming groups of clinical trials8–13 places 
a low, upper bound on the likelihood of such events.
Our cases illustrate how complex and unanticipated 
interactions between manufacturer-specific features 
and generic rate thresholds can withhold therapy for 
VF. Programming manufacturer-preferred values enu-
merated in Appendix B might have prevented some, 
but not all, treatment failures. No patient with man-
ufacturer-specific, programming validated in a clinical 
trial failed to receive an initial, timely shock for VF. Thus 
indirectly, our study supports the recommendation of 
the Consensus Statement7 (Section 23) encouraging 
programming ICDs to manufacturer-specific therapies 
of proven benefit; we recommend such programming 
even if Appendix B permits programming to other val-
ues. Our study identifies risk associated with program-
ming recommendations extrapolated from evidence 
obtained using another manufacturer’s ICDs with dif-
ferent sensing and detection features; however, we 
cannot provide alternative recommendations and do 
not advocate abandonment of any recommendations 
of the Consensus Statement.
Limitations
We did not compare adverse outcomes using evi-
dence-based manufacturer-specific programming and 
more restrictive, generic programming. Although such 
generic programming accounted for 62% of adjudi-
cated sudden deaths in ICD patients at institutions that 
tracked outcomes, our series of cases is too small for 
definitive conclusions.
Even if manufacturer-specific, evidence-based pro-
gramming is available for an ICD, programming more 
restrictive values permitted by the Consensus Statement 
Appendix B may further reduce unnecessary therapies 
and thus further reduce morbidity beyond the reduc-
tion provided by evidence-based programming. How-
ever, the low rate of unnecessary therapy in evidence-
based clinical trials places a low upper bound on the 
incremental benefit of such programming.
Conclusions
Given the rarity of failure to treat VF with evidence-
based, manufacturer-specific programming, failures of 
generic programming constitute a readily preventable 
cause of sudden death. More data are needed to assess 
both the benefits and risks of applying generic pro-
gramming recommendations to specific ICDs in which 
these recommendations have not been validated clini-
cally.
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Supplemental – eResults Text 
Deviation from Consensus Programming (Cases 9 - 10) 
Case 9  
A 14 year-old boy had a primary-prevention, St Jude Medical ICD. In November 2015, he had multiple, 
monomorphic VTs with cycle lengths 260 – 330 ms and underwent catheter ablation that rendered VT 
noninducible. In April 2016, VT recurred at cycle length 285 ms. His amiodarone dose was increased. In 
May 2016, he presented with monomorphic VT slower than the VT interval of 300 ms and became 
hemodynamically unstable. He was treated promptly with external cardioversion. Immediately post-
cardioversion, the rhythm degenerated to VF that the ICD did not detect, and he was defibrillated 
externally.  
Analysis: eFigure 8 shows the undersensed VF. The proprietary Decay Delay algorithm16 may contribute to 
undersensing. See eFigure 8 legend an eFigure 10 for details. 
Case 10  
A 44 year-old man underwent primary-prevention, Medtronic CRT-D implantation in February 2011. From 
May 2011 to September 2016, he had 8 episodes of successfully treated VT or VF (cycle lengths 220 – 270 
ms) without change in programming. In July 2015, amiodarone was started for paroxysmal atrial 
fibrillation; in September 2016, mexiletine was added after a shock for VT at cycle length 265 ms. In 
October 2016, he had a witnessed, cardiac arrest. His wife performed cardiopulmonary resuscitation, and 9 
min later the ICD delivered a shock. She continued resuscitation until, 13 minutes after collapse, 
paramedics arrived, defibrillated him and stabilized him. He recovered over weeks but suffered 
neurological deficits.  
Analysis: As in Case 3, the arrhythmia began with monomorphic VT at cycle length 310 - 330 ms in the 
Monitor zone (eFigure 9). VT persisted for up to 4 min before degenerating to VF, which did not fulfill 
programmed detection criteria for VF or “Fast VT via VF”18 for an additional 5 min (30/40 intervals shorter 
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than 250 or 300 ms, respectively). The initiating VT would have been detected if the VF interval had been 
programmed to validated value of 330 ms (182 bpm); Stored data are insufficient to determine if detection 
would have occurred with an interval of 320 ms.10,12,14,15 See eFigure 9 legend for details.  
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Supplemental – eTables 1 & 2 
eTable 1. Device and implant data 
Case  ICD  Implant 
date* 
 Company ICD model ICD Lead Sinus R-
wave (mV) 
1 Dual Nov 2008, 
Mar 2014 
St Jude 
Medical 
Ellipse DR 2277 
 
Medtronic S6935 
 
8.5 
2 Single Oct 2008 St Jude 
Medical 
Current VR  RF 
1207-36 
St Jude Medical 
Durata 7120 
11.4 
3 CRT-D Feb 2012 Medtronic Protecta XT  
D314TR6 
Medtronic 6947 12.0 
4 CRT-D July 2010, 
May 2012 
St Jude 
Medical 
Unify Quadra 
3251-40 
Medtronic 6947 8.4 
5 Single Sept 2016 Medtronic Evera XT  DVBB1D4 Medtronic 6935  10.9 
6 CRT-D Feb 2010, 
June 2015 
Medtronic Viva XT DTBA1D1 Medtronic 6947 7.8 
7 CRT-D 1994, 2002, 
Aug 2011 
Biotronik Lumax 540 HF-T Guidant Endotak 
Reliance 0158 
8.2 
8 Dual May 2016 Boston 
Scientific 
Autogen EL 
D176DR  
Boston Scientific 
Four-Front 0693  
18.0 
9 Single July 2013 St Jude  
Medical 
Ellipse VR  
1277-36Q 
St Jude Medical 
Durata 7122Q 
>12 
10 CRT-D Feb 2011 Medtronic Viva XT  
DTBA2D1 
St Jude Medical 
Durata 7122 
11.0 
Abbreviation: ATP antitachycardia pacing; ICD implantable cardioverter defibrillator; SVT supraventricular 
tachycardia; VT ventricular tachycardia; VF ventricular fibrillation.  
*The second and third dates represent the time for generator replacement.  
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eTable 2. Deaths and cardiac arrests during the study period at Sites 1 and 2 
 Site 1 
(n=995)* 
Site 2 
(n=648)* 
Total 
Patients in case series (failure of timely VF therapy)    
Resuscitated cardiac arrest  3 0 3 
Sudden death 3 2 5 
Total events (failure of timely VF therapy) 6 2 8 
Patients not included     
Resuscitated cardiac arrest 0 0 0 
Cardiac death (9) (7) (16) 
   Heart failure 6 6 12 
   Sudden death   (4) 
      Not due to failure of timely VF therapy† 2 1 3 
      Unknown‡ 1 0 1 
Vascular death    
   Stroke 1 1 2 
   Peripheral vascular 2 0 2 
Non-cardiovascular death 15 7 22 
Total events     
   No failure of timely VF therapy 26 15 41 
   Unknown sudden death 1 0 1 
* Number of ICD and CRT-D patients under follow-up on January 1, 2017. 
† Two patients died of pulseless electrical activity; 1 died of VF that was sensed and detected reliably but 
was refractory to 6 ICD shocks because of a fractured conductor to the RV shock coil. 
‡ One paJent suﬀered a cardiac arrest and was transported to another hospital. The ICD was not 
interrogated, and no additional data are available. 
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Supplemental – eFigures 1 to 10 
eFigure 1 (Case 1). 
 
Stored EGM displayed as 4 continuous panels displays filtered atrial EGM (A Sense Amp), filtered RV sensing EGM (V Sense Amp), shock EGM (RV coil- Can, 
“Discrimination”), dual-chamber markers, ventricular intervals in ms, and timeline in seconds (s). Panel 1 shows ongoing monomorphic VT at cycle length of 
387 – 395 ms, slower than the programmed VT detection interval of 315 ms. The rhythm becomes polymorphic at 6 s (end of Panel 1) and then degenerates 
to VF, which is detected at 13.4 s (beginning of Panel 3). The ICD delivers antitachycardia pacing (ATP, STIM markers, 13.4 – 14.9 s) while charging (line of 
small asterisks, 13.4 – 21.8 s). However, at 22.4 s (Panel 4) the ICD classifies the rhythm as “sinus,” aborting the shock and resetting VT and VF counters to 0 
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(“Return to Sinus” marker). Markers denote intervals classified (“binned”) in the Sinus zone (VS), VT zone (T), or VF zone (F). Intervals are not binned (–) in 
any zone if zones differ for the index interval and its average with preceding 3 intervals.16 In St. Jude Medical ICDs, Return to Sinus occurs when a 
programmable number of consecutive classified (binned) intervals are slower than the slowest detection interval. In this case Return to Sinus was 
programmed to the nominal value of 5 intervals (range 3 – 7 intervals). Subsequently, clinical polymorphic VT/VF did not satisfy the programmed number of 
intervals for detection of VT (24 intervals shorter than 315 ms) or VF (12 intervals shorter than 240 ms). Undersensing of low-amplitude VF EGMs following 
high-amplitude VF EGMs was critical in erroneous premature termination the device-defined VF episode and aborting the shock. Downward arrows in Panel 3 
denote one example in which 6 sequential VF EGMs are not sensed following a high-amplitude EGM, despite accurate sensing of signals with comparably low 
amplitude toward the end of Panel 2. Undersensing occurs because EGM amplitude decreases faster than dynamically-adjusting sensitivity can adapt. The 
critical undersensing event occurs at 21.2 s (*, Panel 4) following 3 sequentially undersensed EGMs with amplitude 0.91 - 1.1. mV (3 upward arrows). 
Undersensing these EGMs results in a device-defined ventricular interval of 852 ms (VS marker). The subsequent EGM is sensed accurately with an interval of 
332 ms (black box), resulting in the critical, fiNh consecuJve binned, VS interval (†) and premature episode terminaJon. However, if VT detecJon had been 
programmed to clinically-tested VF-interval value of 333 ms, the 332 ms interval would have been unclassified (-), and premature episode termination would 
not have occurred. Since the ICD completed charging during the 852 ms interval (end of line of asterisks), it would have delivered the shock synchronous with 
the EGM ending the 254 ms interval aNer the † EGM (ﬁrst binned VT or VF interval aNer charging). VS2 = events sensed on the Discrimination (shock) channel. 
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eFigure 2 (Case 2). 
 
Failure to treat VF. Stored EGMs display filtered RV dedicated-bipolar sensing EGM (V Sense Amp), 
ventricular markers, ventricular intervals in ms, and timeline in seconds (s). These multiple device-defined 
episodes were recorded during a single clinical VT/VF episode. A. Monomorphic VT at 3:11 PM. The 3 
continuous panels show that VT begins an unknown time before the recording. The VT cycle length 
straddles the Sinus-VT boundary of 300 ms so that multiple intervals in Panel 2 remain unclassified. VT is 
detected at 15.4 s in Panel 3 (VT(ATP----…)) and ATP is delivered immediately (STIM markers). After ATP, VT 
slows to 318- 332 ms in the Sinus zone, resulting in episode termination (“Return to Sinus”) B. VF. The next 
stored EGM recorded about a minute later shows detection of VF. It is likely that the monomorphic VT 
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degenerated to VF in the interval between the two recordings. Panels 1- 5 panels shows stored EGMs from 
sequential Episodes 1 - 3 in which VF detection criteria were met (12 intervals shorter than 250 ms) but 
shocks were aborted due to undersensing that caused premature episode termination. Panels 1 - 3 shows 
Episode 1 which begins after the onset of clinical VF. The ICD charges in Panel 2; but in Panel 3, 5 
consecutive binned intervals longer than the VT interval of 300 ms terminate the VF episode prematurely 
(“Return to Sinus”). Panels 4 and 5 show the ends of VF Episode 2 and Episode 3, respectively. Both 
episodes were aborted by 5 consecutive binned intervals longer than the VT interval. Panel 6 shows the 
end of Episode 4 in which a shock was finally delivered to terminate VF. The mV calibration marker shows 
that VF EGMs have relatively high base-peak amplitudes of 5 - 10 mV for larger EGMs and 1-2 mV for most 
undersensed EGMs. Asterisks denote selected undersensed EGMs that contributed to premature episode 
termination due combined effects of highly-variable EGM amplitudes, the high programmed Threshold 
Start of 62.5%, and the programmed Decay Delay of 60 ms. See eFigure 10. 
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eFigure 3 (Case 3). 
 
EGMs and interval plot transmitted with Lead Integrity Alert  Atrial, RV wide-band filtered sensing channel (RV Tip- RV Ring), and dual-chamber marker 
channel are shown. Panel 1 shows the onset of monomorphic VT at 10:02. Event storage is triggered by the 8 intervals shorter than the programmed VF 
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detection interval (300 ms FS markers). In Panel 2 (continuous with Panel 1) VT cycle length then slows to 290 – 330 ms in the Monitor zone. The end of the 
dotted horizontal line arrows spanning Panels 1 and 2 indicates when VF would have been detected with a clinically-validated detection interval of 330 ms 
(182 bpm). Panel 3 shows the interval plot for the corresponding Monitored Episode which begins simultaneously and lasts for 35 min. Rapid “nonsustained” 
VT episodes were stored intermittently for 46 min until 10:48 AM. Panels 4 - 6 show representative examples during continuous monomorphic and 
polymorphic VT that never fulfilled the VF detection criteria of 30/40 intervals shorter than 300 ms. Ventricular intervals are denoted VS in the Sinus or 
Monitor zone, FS in the VF zone, BV for bi-ventricular paced. Atrial markers denote pacing (AP), blanking-period sensing (AB), and refractory-period sensing 
(AR).
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eFigure 4 (Case 4). 
 
A. Surface ECGs recorded at 25 mm/s by paramedics from defibrillation electrodes during resuscitation. In 
Panels 1 and 2, parallel vertical lines denote 360 J external defibrillation. Panel 1 shows defibrillation of VF 
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to monomorphic VT. Panel 2 shows cardioversion of VT to a slower wide-complex tachycardia; ventricular 
pacing pulses at 130 bpm do not capture. Panel 3 was recorded about 1 min after Panel 2 without 
intervention. It shows atrial pacing with intact AV conduction and premature atrial and ventricular 
complexes. B. Continuous ICD EGMs during one of 3 episodes of monomorphic VT detected and treated by 
the ICD after external defibrillation and during the 70-min resuscitation. Atrial EGM, wide-band filtered 
left-ventricular bipolar EGM, and narrow-band filtered RV sensing EGM are shown with markers. Panel 1 
begins as ongoing VT accelerates into the VT zone (faster than 300 ms). The onset of VT is not recorded. In 
Panel 2, detection of VT is delayed by undersensing of low-amplitude EGMs (asterisks). Note the 
discrepancy between mostly monomorphic LV EGMs and RV EGMs which have variable amplitude and 
morphology. At right of Panel 2, parallel vertical lines and “VT” denote detection of VT. In the next panel 
(not shown), ATP terminates VT to atrial-sensed, biventricular paced rhythm.  
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eFigure 5 (Case 5). 
 
Selected EGMs show RV integrated bipolar EGM (RV Tip – RV Coil), shock EGM (Can - RV Coil), and 
ventricular markers. The ICD did not record the onset of VF. It recorded the first device-defined, 
nonsustained episode (Episode 1) at 03:48. A. Nonsustained Episode 6 at 03:49 is the last episode recorded 
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before the first external defibrillation. VF EGMs have a low frequency content and do not fulfil the-
programmed detection criteria for either VF (18/24 intervals shorter than 300 ms or VT (40 consecutive 
intervals shorter than 320 ms). Intervals in the VT zone do not contribute to detection because 
consecutive-interval counting causes each interval in the sinus zone (320 ms or greater) to reset the VT 
count to 0. After external defibrillation, Monitored Episode 7 (03:53, not shown) displayed a regular 
tachycardia accelerating from 400 to 380 ms, documented to be sinus tachycardia by surface ECG. B. 
Nonsustained Episode 8 recorded at 03:55 AM. Monomorphic VT begins almost isorhythmic with sinus 
tachycardia, and then accelerates but remains slower than the VT zone. It degenerates to polymorphic VT 
with cycle length 310-350 ms toward the end of Panel 3. The ICD-defined episode is triggered by double 
counting of VT EGMs at right of Panel 3. C. VF Episode 9 at 03:58. Six continuous panels show polymorphic 
VT with cycle length 270 – 430 ms that does not satisfy interval/duration criteria for detection and requires 
a second external shock (Panel 2, up arrow). If the VF interval had been programmed to the clinically-
validated values of 320 or 330 ms, this polymorphic VT would have satisfied the programmed 18/24 
intervals for detection of VF (end of dotted arrow in Panels 1 and 2). However, the Lead Integrity Alert18 
was activated incorrectly during Episode 5 when both oversensing criteria were fulfilled. This alert 
increased the number of intervals for VF detection to 30/40 during Episode 6 and subsequent episodes. 
Because the external shock intervened, we cannot determine if the ICD would have detected VF. After the 
shock, VT recurred following the second paced beat and immediately accelerated to VF. The frequency 
content of EGMs was higher during this VF than during the first VF or the polymorphic VT above. The ICD 
detected VF rapidly (Panel 4, “VF Rx 1 Deﬁb”) and deﬁbrillated it with a single shock Panel 5 (†, CD marker, 
36.3 J). Although the Lead Integrity Alert extended detection duration from 18/24 to 30/40 intervals during 
Episode 5, it did not delay detection of polymorphic VT/VF during Episodes 5, 6, and 8 because none 
fulfilled the 18/24 criterion. For the VF in Episode 9, the Lead Integrity Alert’s delay was not significant 
(approximately 12 x 200 ms = 2.4 s). 
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eFigure 6 (Case 6). 
 
Stored and real-time EGMs transmitted with Lead Integrity Alert. A. Stored EGM with same atrial and RV EGMs as Figure 2 provides a representative 
example of the 12 “nonsustained” episodes recorded during the clinical event. B. Real-time EGM during the transmission showing these two EGMs and two 
far-field channels, shock (Can to RV Coil) and “Leadless ECG” (LECG, Can to SVC Coil). The wide-band filtered dedicated bipolar RV sensing EGM shows 
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multiple low amplitude, low-frequency VF EGMs that never fulfil the programmed cycle duration and length and criteria for VF (30/40 intervals shorter than 
300 ms). Some larger EGMs are undersensed because they time in post-ventricular pacing blanking period. Asterisks Panel 1 of section A and Panel 3 of 
section B denote selected undersensed EGMs. VT was not detected despite a long VT detection interval because Medtronic ICDs use consecutive-interval 
counting in the VT zone: any undersensed event resulting in device-measured RR interval ≥ 400 ms resets the VT count to 0. AP = atrial pacing; VP = 
ventricular pacing, BP = biventricular pacing. 
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eFigure 7 (Case 8). 
 
Post-shock undersensing of VF. Atrial EGM A. integrated bipolar sensing EGM (RV) and Can-RV Coil EGM 
(Shock) are shown with dual-chamber markers and intervals. Monomorphic VT persisted for an unknown 
interval before accelerating across the 375 ms Sinus-Monitor zone rate boundary, 13 s before Panel 1. 
Panel 2, continuous with Panel 1, shows monomorphic VT degenerating to VF, which was detected rapidly 
and shocked successfully after a 6.5 s delay (Panel 3). This initiated a repetitive sequence of recurrent VF 
immediately after each shock. Continuous Panel 4 shows the first recurrence. The amplitude of the sensing 
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EGM decreased progressively in successive post-shock recurrences of VF. After the sixth successful 
defibrillation, the amplitude of the VF EGMs was so low that EGMs were undersensed consistently (Panel 
5) and dual-chamber pacing (AP/VP markers) continue through VF. Some VF EGMs were sensed starting a 
few seconds later (Panel 6), but persistent undersensing of low-amplitude EGMs prevented detection of 
VF. B. Insert shows programmer screen shot of Panel 5 with RV EGM at high gain so that low amplitude VF 
EGMs are clearly visible. 
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eFigure 8 (Case 9). 
 
Stored nonsustained episode shows the onset of VF immediately after external cardioversion (not recorded). In each panel, the RV unipolar tip EGM is 
displayed on the first and third channels with the narrow-band filtered, dedicated bipolar EGM on the second channel. Markers, intervals (ms), and timeline 
(s) are displayed at bottom. VF begins between 7 and 8 s on Panel 2. In VF, higher-amplitude, higher-frequency fractionated signals are separated by 
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approximately 300 – 500 ms intervals with isoelectric baseline or low-amplitude signals. Undersensing occurs both because of low-amplitude signals and 
because Decay Delay does not permit sensing immediately after expiration of the sensing blanking period (125 ms). In Panel 3, asterisks denote undersensed 
EGMs. Despite many short intervals, too few satisfy St. Jude Medical’s interval average plus interval count criterion to be classified as VF intervals, shorter 
than 240 ms. No intervals are measured in the VT zone of 250 – 299 ms. The episode ends at 30 s with a total VF count of 11, seven less than the 
programmed value for detection. We do not know if VF would have been detected eventually because the patient was defibrillated externally approximately 
5 seconds later (not shown). 
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eFigure 9 (Case 10). 
 
Untreated monomorphic VT degenerates to untreated polymorphic VT/VF with VF detection programmed to 30/40 intervals shorter than 300 ms. Atrial, RV 
wide-band filtered, dedicated bipolar sensing channel (RV Tip- RV Ring), and dual-chamber marker channel are shown. A. Panel 1 shows the onset of 
monomorphic VT at 320 ms in the monitor zone at 10:30. The end of the dotted arrow in Panels 1 and 2 indicates where VF would have been detected if the 
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detection interval was programmed to the clinically validated value of 330 ms. The recording is suspended for 3 min and 50 s at end of Panel 2. The episode 
ends in Panel 3, likely due to transient entrance block into the region of the sensing bipole during polymorphic VT/VF. B. Within a minute of episode 
termination, a “nonsustained” episode is redetected at 10:34 in which relatively monomorphic VT transforms to polymorphic VT. Repetitive “nonsustained” 
polymorphic VT episodes were detected over the next 5 min. These represent ongoing polymorphic VT/VF that do not fulfill the programmed detection 
criteria. C. Continuous panels recorded at 10:39 show the end of the episode in which VF is detected and shocked (CD, 36.3 J to atrial paced (AP), 
biventricular-paced (BP) rhythm, probably pulseless electrical activity based on clinical data. Repetitive nonsustained episodes begin 5 min after defibrillation 
and continue for an additional 6 min (not shown). These likely representing recurrent VF. 
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eFigure 10. 
 
St. Jude Medical sensing enhancements to minimize T-wave oversensing, modified with permission from 
figures provided by St. Jude Medical. A. Decay delay and Threshold Start. The R-wave signal is rectified. 
After a sensed event (of minimum value 1 mV and maximum value 6mV) a dynamic sensitivity decay start 
linearly at 3mV/s at a programmable percentage of the R-Wave (Threshold Start). Decay Delay increases 
the interval from the end of the blanking period (“Sensed Refractory Period) to the start of the dynamic 
sensitivity decay. The dotted green line show the dynamic sensitivity when Decay Delay is 0 ms instead of 
60 ms and Threshold Start is 50% instead of 62.5%. Red dots denote timing at which EGM crosses 
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threshold and is sensed. B. Low Frequency Attenuation Filter. This filter decreases the amplitude of the low 
frequency signals such as T waves. The figure shows simulated signals including surface ECG lead II, 
narrow-banded filtered atrial EGM (blue), narrow-banded filtered ventricular EGM (brown), and marker 
channels. The filter is turned on at the dotted vertical line. With filter ON, amplitude of simulated R waves 
is unchanged, but the amplitude of simulated T waves is reduced. AS/VS = atrial/ventricular sensed event. 
